Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer − PORTEC-4a an international, randomised, phase 3 trial

Key Points

• Individualized adjuvant treatment based on the molecular-integrated profile is more cost-effective than standard VBT.
• This comparative analysis demonstrates a significant improvement in cost-utility for patients with high intermediate risk endometrial cancer.
• Utilizing a randomized phase 3 trial design aids in validating the effectiveness of the molecular-integrated-profile approach.
• The findings support potential changes in clinical practice regarding treatment strategies for high intermediate risk endometrial cancer.

Abstract